Development of drug eluting biodegradable extravascular stent to prevent vein graft failure

• Project/Area Number: 25861224
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular surgery
• Research Institution: Tohoku University
• Principal Investigator: KAWATSU SATOSHI 東北大学, 大学病院, 助教 (80633685)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 冠動脈バイパス術 / 生体吸収性薬物徐放血管外ステント / ラパマイシン / 静脈グラフト / 新生内膜 / コンプライアンスミスマッチ / 冠動脈外科学 / 薬物溶出性血管外ステント

Outline of Final Research Achievements

Vein graft stenosis and occlusion at long term have been a significant clinical issue. We tested the hypothesis that drug eluting biodegradable extravascular stent can prevent vein graft stenosis by suppressing an increase in the hemodynamic stress and also by inhibiting excessive cellular proliferation. We developed rapamycin (RM) eluting biodegradable poly L-lactic acid and epsilon-caprolactone copolymer (PLA-CL) extravascular stent.Femoral vein graft interposition was performed in beagles. Beagles were divided into four groups: without a stent (control); with a PLA-CL stent only; and with a PLA-CL stent containing RM 80 μg, and with 800 μg. Pathohistologic analyses were performed at 12-month interval.
Rapamycin eluting biodegradable extravascular stent can modify the long-term deterioration of vein graft compliance. In addition, the drug eluting extravascular stent can inhibit neointimal hyperplasia of vein grafts and prevent graft stenosis at long term.